Clinical Trial Update: Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection [Phase 1]

View source ↗

Summary

The Phase 1 trial of IMC-I109V for non-cirrhotic, HBeAg-negative chronic hepatitis B infection has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• IMC-I109V

Snippet

Sponsor: Immunocore Ltd | Conditions: Hepatitis B, Chronic | Phase 1 | Status: WITHDRAWN